Data | Ora | Fonte | Titolo | Simbolo | Compagnia |
28/05/2024 | 14:30 | GlobeNewswire Inc. | Sight Sciences Announces Publication of a New Analysis from The ROMEO Study Showing Meaningful Pressure and Medication Reductions Achieved with OMNI® Across Mild, Moderate, and Advanced Glaucoma | NASDAQ:SGHT | Sight Sciences Inc |
21/05/2024 | 02:56 | Edgar (US Regulatory) | Form 4 - Statement of changes in beneficial ownership of securities | NASDAQ:SGHT | Sight Sciences Inc |
17/05/2024 | 22:16 | Edgar (US Regulatory) | Form 144 - Report of proposed sale of securities | NASDAQ:SGHT | Sight Sciences Inc |
07/05/2024 | 22:05 | GlobeNewswire Inc. | Sight Sciences to Present at the Upcoming Bank of America Healthcare Conference | NASDAQ:SGHT | Sight Sciences Inc |
06/05/2024 | 22:16 | Edgar (US Regulatory) | Form 10-Q - Quarterly report [Sections 13 or 15(d)] | NASDAQ:SGHT | Sight Sciences Inc |
02/05/2024 | 22:05 | GlobeNewswire Inc. | Sight Sciences Reports First Quarter 2024 Financial Results and Reaffirms Full Year 2024 Financial Guidance | NASDAQ:SGHT | Sight Sciences Inc |
29/04/2024 | 14:05 | GlobeNewswire Inc. | Sight Sciences Announces Successful $34 Million Patent Infringement Verdict Against Alcon and its Hydrus Microstent for Microinvasive Glaucoma Surgery | NASDAQ:SGHT | Sight Sciences Inc |
18/04/2024 | 22:05 | GlobeNewswire Inc. | Sight Sciences to Report First Quarter Financial Results on May 2, 2024 | NASDAQ:SGHT | Sight Sciences Inc |
10/04/2024 | 22:05 | GlobeNewswire Inc. | Sight Sciences Announces the Publication of Large-Scale, Real-World MIGS Study Demonstrating the Comprehensive Aqueous Outflow Restorative Procedure with OMNI® Surgical System Technology is Effective at Lowering Both IOP and IOP Reducing Medications at 2 | NASDAQ:SGHT | Sight Sciences Inc |
02/04/2024 | 22:05 | GlobeNewswire Inc. | Sight Sciences Announces the Results of the Three-Year Prospective GEMINI Trial and the Cross-Over Phase of the SAHARA RCT at the 2024 American Society of Cataract and Refractive Surgery (ASCRS) Annual Meeting | NASDAQ:SGHT | Sight Sciences Inc |
26/03/2024 | 21:05 | GlobeNewswire Inc. | Sight Sciences to Present at the Upcoming 23rd Annual Needham Healthcare Conference | NASDAQ:SGHT | Sight Sciences Inc |
07/03/2024 | 22:05 | GlobeNewswire Inc. | Sight Sciences Reports Fourth Quarter and Full Year 2023 Financial Results and Initiates Full Year 2024 Financial Guidance | NASDAQ:SGHT | Sight Sciences Inc |
22/02/2024 | 22:05 | GlobeNewswire Inc. | Sight Sciences to Report Fourth Quarter and Full Year 2023 Financial Results on March 7, 2024 | NASDAQ:SGHT | Sight Sciences Inc |
14/02/2024 | 23:24 | Edgar (US Regulatory) | Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] | NASDAQ:SGHT | Sight Sciences Inc |
14/02/2024 | 22:05 | GlobeNewswire Inc. | Sight Sciences Announces European Launch of the Ergo-Series of the OMNI® Surgical System at the ESCRS Winter Meeting | NASDAQ:SGHT | Sight Sciences Inc |
07/02/2024 | 21:01 | Edgar (US Regulatory) | Form SC 13G - Statement of acquisition of beneficial ownership by individuals | NASDAQ:SGHT | Sight Sciences Inc |
02/02/2024 | 22:02 | Edgar (US Regulatory) | Form 8-K - Current report | NASDAQ:SGHT | Sight Sciences Inc |
23/01/2024 | 22:05 | GlobeNewswire Inc. | Sight Sciences Announces the Closing of up to $65 Million Senior Secured Credit Facility with Hercules Capital | NASDAQ:SGHT | Sight Sciences Inc |
08/01/2024 | 22:05 | GlobeNewswire Inc. | Sight Sciences Announces Preliminary, Unaudited Fourth Quarter and Full Year 2023 Financial Highlights | NASDAQ:SGHT | Sight Sciences Inc |
28/12/2023 | 15:15 | GlobeNewswire Inc. | Sight Sciences Announces Withdrawal of Final LCDs on Micro-Invasive Glaucoma Surgery from Five Medicare Administrative Contractors | NASDAQ:SGHT | Sight Sciences Inc |
18/12/2023 | 22:05 | GlobeNewswire Inc. | Sight Sciences Announces the Publication of Successful Results of the SAHARA Randomized Controlled Clinical Trial Comparing TearCare® to Restasis® for the Treatment of Dry Eye Disease | NASDAQ:SGHT | Sight Sciences Inc |
08/12/2023 | 14:05 | GlobeNewswire Inc. | Sight Sciences Announces the Acceptance for Publication of GEMINI 2, a Three Year, Prospective, Multicenter Trial Demonstrating Sustained, Significant IOP and Medication Reductions Enabled with the OMNI® Surgical System Technology | NASDAQ:SGHT | Sight Sciences Inc |
01/12/2023 | 22:05 | Edgar (US Regulatory) | Form SC 13D/A - General statement of acquisition of beneficial ownership: [Amend] | NASDAQ:SGHT | Sight Sciences Inc |
16/11/2023 | 23:35 | Edgar (US Regulatory) | Form 4/A - Statement of changes in beneficial ownership of securities: [Amend] | NASDAQ:SGHT | Sight Sciences Inc |
07/11/2023 | 22:05 | GlobeNewswire Inc. | Sight Sciences Reports Third Quarter 2023 Financial Results and Withdraws Guidance for Full Year 2023 | NASDAQ:SGHT | Sight Sciences Inc |
24/10/2023 | 22:05 | GlobeNewswire Inc. | Sight Sciences to Report Third Quarter 2023 Financial Results on November 7, 2023 | NASDAQ:SGHT | Sight Sciences Inc |
19/10/2023 | 22:05 | GlobeNewswire Inc. | Sight Sciences to Host SAHARA 6 Month RCT Results Reception at the American Academy of Ophthalmology 2023 | NASDAQ:SGHT | Sight Sciences Inc |
12/10/2023 | 22:05 | GlobeNewswire Inc. | Sight Sciences Announces Presentation of Successful Phase I Results of the SAHARA Randomized Controlled Clinical Trial Comparing TearCare® to Restasis® for the Treatment of Dry Eye Disease at the American Academy of Optometry Annual Meeting | NASDAQ:SGHT | Sight Sciences Inc |
03/10/2023 | 14:30 | GlobeNewswire Inc. | Sight Sciences Announces New, Large-Scale MIGS Data from 41st Congress of ESCRS Demonstrating TCOR™ Using OMNI® Surgical System Technology is Effective at Lowering Both IOP and IOP Reducing Medications at 2 Years in Patients with Glaucoma | NASDAQ:SGHT | Sight Sciences Inc |
12/09/2023 | 15:23 | IH Market News | Keep An Eye Out: Pre-Market Movers And Recommendations | NASDAQ:SGHT | Sight Sciences Inc |